A high-throughput screening assay for determining cellular levels of total tau protein

Current Alzheimer Research

Volumn 10, Issue 7, 2013, Pages 679-687

  Dehdashti, Seameen J ^a   Zheng, Wei ^a   Gever, Joel R ^b   Wilhelm, Robert ^b   Nguyen, Dac Trung ^a   Sittampalam, Gurusingham ^a   Mckew, John C ^a   Austin, Christopher P ^a   Prusiner, Stanley B ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; FRET based assay; High throughput screening assay; Neurodegenerative diseases; Prions; Tau protein

Indexed keywords

5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; CHAPERONIN; DIGOXIN; MELPHALAN; METHYLENE BLUE; MICROTUBULE ASSOCIATED PROTEIN; TAU PROTEIN; TYRPHOSTIN; WORTMANNIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DENSITY; CELL LEVEL; CEREBROSPINAL FLUID; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOTOXICITY; ELECTRONICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TAUOPATHY; WESTERN BLOTTING;

ALZHEIMER DISEASE; ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FIBROBLASTS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; TAU PROTEINS;

EID: 84888259390     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990143     Document Type: Article

References (37)

1. toothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 1739: 280-297 (2005).
2. Yoshiyama Y, Uryu K, Higuchi M, Longhi L, Hoover R, Fujimoto S, et al. Enhanced neurofibrillary tangle formation, cerebral atrophy, and cognitive deficits induced by repetitive mild brain injury in a transgenic tauopathy mouse model. J Neurotrauma 22: 1134-1141 (2005).
3. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83: 4044-4048 (1986).
4. Smith DH, Chen XH, Nonaka M, Trojanowski JQ, Lee VM, Saat-man KE, et al. Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol Exp Neurol 58: 982-992 (1999).
5. Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 117: 5721-5729 (2004).
6. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393: 702-705 (1998).
7. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282: 1914-1917 (1998).
8. Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 8: 423-34 (2012).
9. Prusiner SB. A unifying role for prions in neurodegenerative diseases. Science 336: 1511-1513 (2012).
10. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284: 12845-12852 (2009).
11. Guo JL, Lee VM-Y. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 286: 15317-15331 (2011).
12. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in trans-genic mouse brain. Nat Cell Biol 11: 909-913 (2009).
13. Braak H, Braak E. Staging of Alzheimer's disease-related neurofi-brillary changes. Neurobiol Aging 16: 271-284 (1995).
14. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7: e31302 (2012).
15. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Ada-mowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73: 685-697 (2012).
16. Polymenidou M, Cleveland DW. Prion-like spread of protein aggregates in neurodegeneration. J Exp Med 209: 889-893 (2012).
17. Gomez de Barreda E, Perez M, Gomez Ramos P, de Cristobal J, Martin-Maestro P, Moran A, et al. Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis 37: 622-629 (2010).
18. Evans CG, Jinwal UK, Makley LN, Dickey CA, Gestwicki JE. Identification of dihydropyridines that reduce cellular tau levels. Chem Commun (Camb) 47: 529-531 (2011).
19. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal degradation of tau protein. J Neurochem 83: 176-185 (2002).
20. Keck S, Grafe A, Ullrich O, Grune T. Degradation of tau - Does the proteasomal system play a role? Neurobiol Aging 25: S422 (2004).
21. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmech-elen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26: 231-245 (1995).
22. Loffler T, Flunkert S, Taub N, Schofield EL, Ward MA, Windisch M, et al. Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates. J Mol Neu-rosci 47: 192-203 (2012).
23. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, Austin CP, et al. High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3: 466-479 (2007).
24. Inglese J, Johnson RL, Simeonov A, Xia MH, Zheng W, Austin CP, et al. High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3: 466-479 (2007).
25. Jinwal UK, Miyata Y, Koren J, 3rd, Jones JR, Trotter JH, Chang L, et al. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci 29: 12079-12088 (2009).
26. Deng YQ, Xu GG, Duan P, Zhang Q, Wang JZ. Effects of mela-tonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sin 26: 519-526 (2005).
27. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370: 1209-1218 (2007).
28. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Dis-cov 4: 988-1004 (2005).
29. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem 49: 3857-3871 (2006).
30. Pickhardt M, von Bergen M, Gazova Z, Hascher A, Biernat J, Mandelkow EM, et al. Screening for inhibitors of tau polymerization. Curr Alzheimer Res 2: 219-226 (2005).
31. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology 59: 276-289 (2010).
32. Honson NS, Johnson RL, Huang W, Inglese J, Austin CP, Kuret J. Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis 28: 251-260 (2007).
33. Crowe A, Huang W, Ballatore C, Johnson RL, Hogan AM, Huang R, et al. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48: 7732-7745 (2009).
34. Liu SJ, Wang JZ. Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin 23: 183-187 (2002).
35. Liu M, Choi S, Cuny GD, Ding K, Dobson BC, Glicksman MA, et al. Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors. Biochemistry 47: 8367-8377 (2008).
36. Stoilov P, Lin CH, Damoiseaux R, Nikolic J, Black DL. A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators. Proc Natl Acad Sci USA 105: 11218-11223 (2008).
37. Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, Eckman CB, et al. Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors. Curr Alzheimer Res 2: 231-238 (2005).